Airbus SE vs F. Hoffmann-La Roche AG: Strategic Comparison
Key Differences at a Glance
| Field | Airbus SE | F. Hoffmann-La Roche AG |
|---|---|---|
| Revenue | $79.3B | $77.2B |
| Founded | 1970 | 1896 |
| Employees | 159,000 | 112,774 |
| Market Cap | $135.0B | $327.5B |
| Headquarters | France / Netherlands | Switzerland |
Quick Stats Comparison
| Metric | Airbus SE | F. Hoffmann-La Roche AG |
|---|---|---|
| Revenue | $79.3B | $77.2B |
| Founded | 1970 | 1896 |
| Headquarters | Leiden, Netherlands / Toulouse, France | Basel, Switzerland |
| Market Cap | $135.0B | $327.5B |
| Employees | 159,000 | 112,774 |
Airbus SE Revenue vs F. Hoffmann-La Roche AG Revenue — Year by Year
| Year | Airbus SE | F. Hoffmann-La Roche AG | Leader |
|---|---|---|---|
| 2025 | $79.3B | $77.2B | Airbus SE |
| 2024 | $74.7B | $75.9B | F. Hoffmann-La Roche AG |
| 2023 | $70.6B | $75.9B | F. Hoffmann-La Roche AG |
| 2022 | $62.9B | N/A | Airbus SE |
Business Model Breakdown
Overview: Airbus SE vs F. Hoffmann-La Roche AG
This in-depth comparison examines Airbus SE and F. Hoffmann-La Roche AG across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Airbus SE on its own, evaluating F. Hoffmann-La Roche AG, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Airbus SE and F. Hoffmann-La Roche AG is widest.
On the headline numbers, Airbus SE reports annual revenue of $79.3B against $77.2B for F. Hoffmann-La Roche AG, while their respective market capitalizations stand at $135.0B and $327.5B. Airbus SE is headquartered in France / Netherlands and F. Hoffmann-La Roche AG operates from Switzerland, and those different home markets shape how each company competes.
Airbus SE: Airbus combines scale, leadership, and a clear operating model. The most useful reader path is revenue first, then business model, founders, CEO, competitors, and risk.
F. Hoffmann-La Roche AG: Roche is not just a drug company with a diagnostics side business. Its strategic identity is an integrated healthcare model: test the patient, identify the biology, treat with a targeted therapy, and use outcome data to improve the next development cycle.
Business Models: How Airbus SE and F. Hoffmann-La Roche AG Make Money
Airbus SE and F. Hoffmann-La Roche AG pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Airbus SE and F. Hoffmann-La Roche AG.
Airbus SE business model: Airbus makes money from commercial aircraft deliveries, helicopters, defense and space programs, services and support. The core SEO opportunity is to connect the simple user questions, such as revenue and CEO, with the deeper business-model mechanics that explain why the company earns those numbers.
F. Hoffmann-La Roche AG business model: Roche makes money from branded prescription medicines, biologics, oncology and specialty drugs, diagnostic instruments, diagnostic reagents, sequencing and molecular testing, diabetes care products, and clinical data assets. Pharmaceuticals drive the largest share of sales, while Diagnostics adds recurring reagent revenue and supports personalized healthcare.
Competitive Advantage: Airbus SE vs F. Hoffmann-La Roche AG
The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Airbus SE stack up against those of F. Hoffmann-La Roche AG.
Airbus SE competitive advantage: Airbus's advantage is its aircraft backlog, A320-family scale, cockpit commonality, fuel-efficient platforms, government relationships, and global assembly footprint.
F. Hoffmann-La Roche AG competitive advantage: Roche's advantage is the combination of drug development, diagnostics, Genentech biotechnology depth, companion diagnostic capability, and oncology data assets from Foundation Medicine and Flatiron Health. Competitors can match pieces of this model, but few can connect medicines, tests, and real-world data at similar scale.
Growth Strategy: Where Airbus SE and F. Hoffmann-La Roche AG Are Headed
Future prospects matter as much as current results. The growth strategies below explain how Airbus SE and F. Hoffmann-La Roche AG each plan to expand from here.
Airbus SE growth strategy: Airbus's growth strategy centers on strengthening core products, improving operating efficiency, expanding high-value revenue streams, and using technology and distribution to deepen customer relationships.
F. Hoffmann-La Roche AG growth strategy: Roche is investing in late-stage medicines, diagnostics platforms, sequencing, companion diagnostics, real-world evidence, and selective acquisitions that strengthen oncology, immunology, neuroscience, and cardiovascular-metabolic disease areas.
Financial Picture: Airbus SE vs F. Hoffmann-La Roche AG
A closer look at the financial trajectory of Airbus SE and F. Hoffmann-La Roche AG rounds out the comparison.
Airbus SE: Airbus reported $79.3B in FY2025 revenue and about $5.62B in net income. The financial narrative links annual results to revenue streams, margin drivers, product priorities, and competitive pressure.
F. Hoffmann-La Roche AG: Roche reported CHF 61.5 billion in 2025 group sales. Pharmaceuticals sales were CHF 47.7 billion and Diagnostics sales were CHF 13.8 billion. Core operating profit was CHF 21.8 billion, and R&D core investments were CHF 12.2 billion. For USD comparability, this profile converts CHF 61.5 billion at 1 CHF = 1.25506 USD.
Company-Specific SWOT Notes
Airbus SE
Airbus's advantage is its aircraft backlog, A320-family scale, cockpit commonality, fuel-efficient platforms, government relationships, and global assembly footprint.
Airbus wins because it has built a massive, proprietary digital fly-by-wire architecture combined with an unassailable global final assembly line footprint and a highly optimized Tier-1 supply chain network, creating a level of operational scale, pilot commonality, and airline convenience that no competitor can replicate.
The single biggest risk facing Airbus SE is the extreme volatility and unpredictability of the global Tier-1 aerospace supply chain, specifically the production bottlenecks associated with the Pratt & Whitney PW1100G Geared Turbofan (GTF) engine and the CFM International LEAP-1A powerplant, which serve as the exclusive propulsion systems for the A320neo family.
Airbus's growth strategy centers on strengthening core products, improving operating efficiency, expanding high-value revenue streams, and using technology and distribution to deepen customer relationships.
F. Hoffmann-La Roche AG
Roche's advantage is the combination of drug development, diagnostics, Genentech biotechnology depth, companion diagnostic capability, and oncology data assets from Foundation Medicine and Flatiron Health.
Roche wins by combining medicines, diagnostics, biomarkers, and oncology data into a precision-healthcare model competitors struggle to copy.
The biggest risk is that biosimilar erosion and pricing pressure outrun the replacement power of Roche new launches and late-stage pipeline.
Roche is investing in late-stage medicines, diagnostics platforms, sequencing, companion diagnostics, real-world evidence, and selective acquisitions that strengthen oncology, immunology, neuroscience, and cardiovascular-metabolic disease areas.
Head-to-Head Scorecard
| Category | Winner | Why |
|---|---|---|
| Revenue Scale | Airbus SE | Airbus SE reports the larger revenue base ($79.3B), which serves as a core operational scale signal. |
| Profitability Potential | Comparable | Both organizations prioritize market penetration or are at equivalent reporting tiers. |
| Company Age | F. Hoffmann-La Roche AG | Founded in 1970 vs 1896. The earlier pioneer typically commands longer historical institutional legacy. |
| Innovation Moat | F. Hoffmann-La Roche AG | Higher aggregate count of major acquisitions and key R&D releases indicates a more active technology absorption velocity. |
| Scale (Employees) | Airbus SE | A significantly larger reported workforce supports enhanced global distribution capability. |
| Market Cap | F. Hoffmann-La Roche AG | Higher public valuation denotes greater forward-looking investor conviction in earnings potential. |
| Future Outlook | Tied | Strategic auditing assesses that both maintain defensive leadership vectors within their core market clusters. |
Who Wins Each Category?
Airbus SE reports the larger revenue base ($79.3B), which serves as a core operational scale signal.
Both organizations prioritize market penetration or are at equivalent reporting tiers.
Founded in 1970 vs 1896. The earlier pioneer typically commands longer historical institutional legacy.
Higher aggregate count of major acquisitions and key R&D releases indicates a more active technology absorption velocity.
A significantly larger reported workforce supports enhanced global distribution capability.
Who Wins: Airbus SE or F. Hoffmann-La Roche AG?
Reviewed by Swet Parvadiya, May 2026 - Author Profile
Our analysts compile business strategy profiles from public financial filings, press releases, and analyst reports. Each profile is reviewed for accuracy before publication by our editorial desk and updated on a rolling basis.
Frequently Asked Questions: Airbus SE vs F. Hoffmann-La Roche AG
Is Airbus SE better than F. Hoffmann-La Roche AG?
Verdict: Between Airbus SE and F. Hoffmann-La Roche AG, Airbus SE is the stronger overall option based on higher annual revenue. The decision still depends on which factors matter most for your needs, but on the weight of the evidence above, Airbus SE comes out ahead in this Airbus SE vs F. Hoffmann-La Roche AG comparison.
Who earns more — Airbus SE or F. Hoffmann-La Roche AG?
Airbus SE earns more with $79.3B in annual revenue versus F. Hoffmann-La Roche AG's $77.2B. Airbus SE leads on total revenue based on latest verified figures.
Which company has higher revenue — Airbus SE or F. Hoffmann-La Roche AG?
Airbus SE reported $79.3B, while F. Hoffmann-La Roche AG reported $77.2B. The revenue leader is Airbus SE based on latest verified figures.
Airbus SE revenue vs F. Hoffmann-La Roche AG revenue — which is higher?
Airbus SE revenue: $79.3B. F. Hoffmann-La Roche AG revenue: $77.2B. Airbus SE has the larger revenue base of the two companies.
Sources & References
- Airbus SE Corporate Website
- Airbus SE Annual Report 2025 - Revenue and Financial Data
- airbus.com
- airbus.com
- airbus.com
- airbus.com
- airbus.com
- F. Hoffmann-La Roche AG Corporate Website
- F. Hoffmann-La Roche AG Annual Report 2025 - Revenue and Financial Data
- roche.com
- roche.com
- assets.roche.com
- roche.com
- stockanalysis.com
- ofx.com